Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1Breast 1

Conditions

Skin Neoplasms 2Carcinoma, Basal Cell 2Precancerous Conditions 1Non-melanoma Skin Cancer 1Melanoma 1Keratosis, Actinic 1Breast Neoplasms 1

Interventions

pembrolizumab 21Cyclophosphamide 18fludarabine 8Radiotherapy 8Radiosurgery 7Nivolumab 7poly ICLC 6fludarabine phosphate 6aldesleukin 6Therapeutics 6Paclitaxel 6Magnetic Resonance Spectroscopy 6durvalumab 5Psychiatric Rehabilitation 5Interleukin-2 5Drug Therapy 5Docetaxel 5Cisplatin 5temsirolimus 4cemiplimab 4Trastuzumab 4Temozolomide 4Sirolimus 4Gemcitabine 4Flow Cytometry 4Filgrastim 4Carboplatin 4tremelimumab 3technetium-diethylenetriaminepentaacetic acid-mannosyl-dextran 3pazopanib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Breast Neoplasms × Eflornithine × Dermatologic × Clear all
NCT07287917 2026-05-12

Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors

Aminex Therapeutics, Inc.

Phase 1/2 Recruiting
92 enrolled
BreastDermatologic

Breast Neoplasms, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡